Based on experience with 30 men having clinical stage A and B adenocarcinoma of the prostate, the authors conclude that elevation of bone marrow acid phosphatase (BMAP) is a sensitive indicator of the disease state. BMAP revealed periprostatic or nodal Involvement when osseous metastases seemed absent. BMAP is considered essential in the evaluation of all patients with prostatic carcinoma. Patients who have false negative BMAP (and are not candidates for radical prostatectomy), should undergo lymphangiography and bone scan before radiation therapy or hormonal treatment is planned.
Kabler, Ronald; Farah, Riad; Greenawald, Kenneth; and Cerny, Joseph C.
"Bone Marrow Acid Phosphatase in the Evaluation of Patients with Carcinoma of the Prostate,"
Henry Ford Hospital Medical Journal
: Vol. 23
Available at: https://scholarlycommons.henryford.com/hfhmedjournal/vol23/iss4/5